Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of infection due to Pneumocystis carinii.

× No keyword cloud information.

61 in total

1. Employment of terbinafine against Pneumocystis carinii infection in rat models.

Authors: C Contini; D Colombo; R Cultrera; E Prini; T Sechi; E Angelici; R Canipari
Journal: Br J Dermatol Date: 1996-06 Impact factor: 9.302

2. Intrapulmonary and systemic pharmacokinetics of aerosolized pentamidine used for prophylaxis of pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus.

Authors: J E Conte; J A Golden
Journal: J Clin Pharmacol Date: 1995-12 Impact factor: 3.126

3. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist.

Authors: W T Hughes; D P Jacobus; C Canfield; J Killmar
Journal: Antimicrob Agents Chemother Date: 1993-07 Impact factor: 5.191

4. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors: S Merali; A B Clarkson
Journal: Antimicrob Agents Chemother Date: 1996-04 Impact factor: 5.191

5. Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.

Authors: W T Hughes; J Killmar
Journal: Antimicrob Agents Chemother Date: 1996-04 Impact factor: 5.191

6. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii.

Authors: M S Bartlett; M Shaw; P Navaran; J W Smith; S F Queener
Journal: Antimicrob Agents Chemother Date: 1995-11 Impact factor: 5.191

Review 7. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

Authors: R J Simonds; W T Hughes; J Feinberg; T R Navin
Journal: Clin Infect Dis Date: 1995-08 Impact factor: 9.079

8. Monitoring of co-trimoxazole concentrations in serum during treatment of pneumocystis carinii pneumonia.

Authors: B Joos; J Blaser; M Opravil; J P Chave; R Lüthy
Journal: Antimicrob Agents Chemother Date: 1995-12 Impact factor: 5.191

9. Surfactant protein-A levels increase during Pneumocystis carinii pneumonia in the rat.

Authors: D S Phelps; T M Umstead; R M Rose; J A Fishman
Journal: Eur Respir J Date: 1996-03 Impact factor: 16.671

10. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group.

Authors: S Safrin; D M Finkelstein; J Feinberg; P Frame; G Simpson; A Wu; T Cheung; R Soeiro; P Hojczyk; J R Black
Journal: Ann Intern Med Date: 1996-05-01 Impact factor: 25.391

17 in total

1. The management of Pneumocystis carinii pneumonia.

Authors: F J Vilar; S H Khoo; T Walley
Journal: Br J Clin Pharmacol Date: 1999-06 Impact factor: 4.335

Review 2. Antiparasitic agent atovaquone.

Authors: Aaron L Baggish; David R Hill
Journal: Antimicrob Agents Chemother Date: 2002-05 Impact factor: 5.191

Review 3. Clindamycin as an antimalarial drug: review of clinical trials.

Authors: Bertrand Lell; Peter G Kremsner
Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191

4. Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.

Authors: Peter D Walzer; Alan Ashbaugh
Journal: Antimicrob Agents Chemother Date: 2002-02 Impact factor: 5.191

5. Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds.

Authors: Melanie T Cushion; Peter D Walzer; Margaret S Collins; Sandra Rebholz; Jean Jacques Vanden Eynde; Annie Mayence; Tien L Huang
Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191

6. Enhanced permeability of the antimicrobial agent 2,5-bis(4-amidinophenyl)furan across Caco-2 cell monolayers via its methylamidoidme prodrug.

Authors: Liao Zhou; Kiho Lee; Dhiren R Thakker; David W Boykin; Richard R Tidwell; James E Hall
Journal: Pharm Res Date: 2002-11 Impact factor: 4.200

Treatment of infection due to Pneumocystis carinii.